David A. Siegel Ngm Biopharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $94,770 - $155,520	-81,000 Reduced 13.8%	505,900 $804,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.31 $67,740 - $147,899	112,900 Added 23.82%	586,900 $504,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $111,930 - $359,242	106,600 Added 29.01%	474,000 $507,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $3,416 - $6,342	-1,400 Reduced 0.38%	367,400 $951,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $146,196 - $212,220	39,300 Added 11.93%	368,800 $1.5 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $145,948 - $553,404	42,800 Added 14.93%	329,500 $1.65 Million
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $1.13 Million - $1.58 Million	89,700 Added 45.53%	286,700 $3.75 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $27,508 - $45,500	2,600 Added 1.34%	197,000 $2.53 Million
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $999,844 - $1.35 Million	-72,400 Reduced 27.14%	194,400 $2.97 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $1.74 Million - $2.22 Million	101,000 Added 60.92%	266,800 $4.73 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $2.65 Million - $3.45 Million	131,600 Added 384.8%	165,800 $3.49 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $106,926 - $213,213	7,100 Added 26.2%	34,200 $674,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $677,229 - $865,303	27,100 New	27,100 $788,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.